Stock INCY INCYTE CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Company Incyte Corporation

Equities

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
51.18 USD -1.08% Intraday chart for Incyte Corporation -3.10% -18.49%
Apr. 24 Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating MT
Apr. 23 Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call

Business Summary

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:

- product sales (85.6%);

- royalties (14.2%);

- income from research and cooperation agreements (0.2%).

Number of employees: 2,524

Sales per Business

USD in Million2022Weight2023Weight Delta
Proprietary Therapeutics
100.0 %
3,395 100.0 % 3,696 100.0 % +8.87%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
95.1 %
3,200 95.6 % 3,500 95.1 % +9.38%
Europe and Japan
4.9 %
-- 179 4.9 % -

Managers

Managers TitleAgeSince
Herve Hoppenot CEO
 Chief Executive Officer 64 14-01-12
Christiana Stamoulis DFI
 Director of Finance/CFO 53 19-02-10
Pablo Cagnoni PSD
 President 60 23-06-04
Steven Stein CTO
 Chief Tech/Sci/R&D Officer 57 15-03-01
Benjamin J. Strain IRC
 Investor Relations Contact - 23-08-31
Sheila Denton LAW
 General Counsel 58 23-09-30
Thomas Tray AUD
 Comptroller/Controller/Auditor 46 05-05-31
Peter Langmuir PRN
 Corporate Officer/Principal - 15-07-31
Michael Morrissey PRN
 Corporate Officer/Principal - 15-12-31
Vijay Iyengar PRN
 Corporate Officer/Principal 51 16-04-30

Members of the board

Members of the board TitleAgeSince
Julian Baker BRD
 Director/Board Member 57 00-12-31
Edmund Harrigan BRD
 Director/Board Member 71 19-12-15
Jean-Jacques Bienaimé BRD
 Director/Board Member 70 15-01-19
Otis Brawley BRD
 Director/Board Member 64 21-09-26
Jacqualyn Fouse BRD
 Director/Board Member 62 17-11-13
Paul Clancy BRD
 Director/Board Member 62 15-01-19
Susanne Antonie Schaffert BRD
 Director/Board Member 57 22-09-30
Herve Hoppenot CEO
 Chief Executive Officer 64 14-01-12
Katherine High BRD
 Director/Board Member 72 20-03-24

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 224,526,128 220,960,599 ( 98.41 %) 0 98.41 %

Shareholders

NameEquities%Valuation
Baker Bros. Advisors LP
16.23 %
36,451,464 16.23 % 2 077 M $
Baker Bros. Advisors LP
16.11 %
36,179,122 16.11 % 2 061 M $
Vanguard Fiduciary Trust Co.
10.03 %
22,519,381 10.03 % 1 283 M $
BlackRock Advisors LLC
8.724 %
19,588,229 8.724 % 1 116 M $
Dodge & Cox
7.166 %
16,090,421 7.166 % 917 M $
STATE STREET CORPORATION
4.507 %
10,120,170 4.507 % 577 M $
Renaissance Technologies LLC
2.474 %
5,553,937 2.474 % 316 M $
Geode Capital Management LLC
1.903 %
4,273,448 1.903 % 243 M $
BlackRock Life Ltd.
1.809 %
4,061,794 1.809 % 231 M $
Eaton Vance Management
1.495 %
3,355,698 1.495 % 191 M $

Holdings

NameEquities%Valuation
MERUS N.V.
6.92%
 4,004,544 6.92% 180,324,616 $

Company contact information

Incyte Corp.

1801 Augustine Cut-Off

19803, Wilmington

+302 498 6700

http://www.incyte.com
address Incyte Corporation(INCY)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per region

Ratings for Incyte Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
51.18 USD
Average target price
75.2 USD
Spread / Average Target
+46.93%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
INCYTE CORPORATION Stock Incyte Corporation
-18.49% 11.62B
CSL LIMITED Stock CSL Limited
-4.55% 87.31B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.63% 40.86B
BIOGEN INC. Stock Biogen Inc.
-21.76% 29.36B
UCB Stock UCB
+58.56% 24.49B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-14.78% 17.31B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-15.61% 11.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-44.02% 11.26B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.17% 8.31B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-9.01% 7.9B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. INCY Stock
  4. Company Incyte Corporation